Tango Therapeutics Stock (NASDAQ:TNGX)
Previous Close
$2.94
52W Range
$2.70 - $13.01
50D Avg
$4.53
200D Avg
$7.57
Market Cap
$333.00M
Avg Vol (3M)
$1.91M
Beta
0.88
Div Yield
-
TNGX Company Profile
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
TNGX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CGEM | Cullinan Oncology, Inc. |
| RVMD | Revolution Medicines, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| RLYB | Rallybio Corporation |
| TYRA | Tyra Biosciences, Inc. |
| CNTB | Connect Biopharma Holdings Limited |
| NRIX | Nurix Therapeutics, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| ARVN | Arvinas, Inc. |
| FHTX | Foghorn Therapeutics Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| XLO | Xilio Therapeutics, Inc. |
| THRD | Third Harmonic Bio, Inc. |
| STTK | Shattuck Labs, Inc. |
| PASG | Passage Bio, Inc. |
| RAPT | RAPT Therapeutics, Inc. |